What impact does disease rarity have on rare and orphan drug pricing?
As more pharmaceutical companies develop and launch drugs to treat rare diseases, reimbursement decisions indicate that payers are looking at a range of...
Bhavesh Patel (PhD) is a Principal in the Life Sciences Practice at CRA. He has managed numerous strategy consulting projects on topics including pricing and market access, value perception, brand strategy, and launch readiness, engaging with pharmaceutical, biotech, and medical device companies.
Bhavesh has experience across various therapeutic areas including rare diseases, oncology, cardiovascular disease, diabetes, autoimmune disease, and ophthalmology. In addition, he is currently managing CRA’s internal “Rare Diseases” issues leadership platform and has published articles and posters (ISPOR) on the role of PAGs in rare diseases and the funding dynamics for gene/cell therapies, respectively.
Prior to CRA, he was an associate consultant at QuintilesIMS where he also gained experience in market research, data analysis, and project management. Prior to that, he was a postdoctoral research associate for the Medical Research Council. He has also worked as a freelance editor in chemistry and as a research intern at GSK, AstraZeneca, and P&G.